Retrospective cohort reveals high hematological response rates in pre-fibrotic myelofibrosis patients treated with peginterferon, suggesting its efficacy.
Key Points
To evaluate responses to pegylated interferon in patients with pre-fibrotic myelofibrosis.
Monocentric study design
Evaluated hematological, molecular, and clinical responses
Followed a cohort of 55 patients
Focused on pre-PMF with JAK2 or CALR mutations
Analyzed outcomes over a median follow-up of 3.89 years.
81% complete hematological response after 24 months
54.6% of JAK2-mutated patients achieved >50% reduction in allele burden
Only one case of blastic transformation reported
73% of patients stabilized their disease
Three thromboembolic events observed in the JAK2 cohort.
Cite This Study
Machherndl‐Spandl et al. (2025) studied this question.